- Hyundai Motor and its union reached a tentative wage deal to end production-disruptive walkouts, while Visa and Mastercard stocks hit record highs due to resilient U.S. consumer spending.
- SpaceX plans to launch Nvidia-powered AI satellites by next year, and the FDA approved an Alzheimer's blood test developed by Roche and Eli Lilly.
- The FTC reached an antitrust settlement with Zillow and Redfin, and the NHTSA expanded its investigation into GM's electronic braking system.
- RemeGen reported a cash balance of RMB 3.84 billion and domestic drug sales of RMB 1.4 billion for H1 2026.
- The company highlighted commercial portfolios like telitacicept and disitamab vedotin, alongside global partnerships with potential value exceeding USD 12 billion.
- Key clinical updates included Phase 3 readouts for telitacicept, notably showing a 55% placebo-adjusted 24-hour UPCR reduction in the IgAN study.
- California canceled a settlement meeting regarding a multistate antitrust lawsuit concerning the Paramount and Warner merger due to leaks.
- The FTC reached an antitrust settlement with Zillow and Redfin to unwind a prior $100 million market-sharing agreement.
- Roche and Eli Lilly obtained FDA approval for a new Alzheimer's disease blood test.